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The ability of human tonsillar lymphoid cells to express growth hormone receptor (hGH-N-R)
was analyzed by flow cytometry. FITC-coupled recombinant human growth hormone (hGH-N)
was used to reveal the receptors, in combination with phenotype markers.
Unlike T cells, tonsillar B cells constitutively express the hGH-N receptor. Quiescent cells
separated from activated cells by Percoll-gradient centrifugation bear fewer receptors than
activated ones. Activated T cells express hGH-N-R, but the typical germinal centre CD4+CD57
T cells do not. These latter thus appear not to be fully activated.
Inside the lymph follicles, the germinal centre CD38 B-cell population and the mantle-zone
CD39 B-cell population display similar levels of hGH-N-R expression, but receptor density is
lower on dividing dark-zone CD38+CD10 B cells.
Different lymphoid-cell populations thus differ markedly in their ability to express the growth
hormone receptor, in relation notably to their activation status. This highlights the link between
the neuroendocrine system and the active immune defense.
Keywords: Human growth hormone receptor, human tonsil, hGH-N, hGH-N-R, FACS, germinal center,
lymph follicle
INTRODUCTION
Several studies have revealed two-way connections
between the immune and the neuroendocrine systems
(Mocchegiani et al., 1990; Murphy et al., 1992;
Blalock, 1994; Clarke and Kendall, 1994; Mathison et
al., 1994; Ottaway and Hurband, 1994; Fabris et al.,
1995; Hooghe-Peters and Hooghe, 1995; Hooghe et
al., 1996). This highly regulated ensemble forms a
network of physiological reactions. Growth hormone
produced by the pituitary, under the control of the
hypothalamus, is one of the main actors in this
network.
Growth hormone (hGH-N), in addition to its well-
known metabolic effects, can modulate the immune
system through its direct action on lymphocytes and
their accessory cells. It is well established that human
lymphoid cells express the growth hormone receptor
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(hGH-N-R) and even produce hGH-N (Kiess and
Butenandt, 1985; Badolato et al., 1994; see for review
Hooghe et al., 1996). The studies establishing these
facts focused solely on crude lymphoid-cell popula-
tions, taking no account of the activation or matura-
tion levels of subpopulations present.
Here we have examined expression ofhGH-N-R by
lymphocyte subpopulations freshly prepared from
human tonsillar lymph follicles and by a mitogen-
activated lymphocyte population. We have addressed
the question: Does hGH-N-R expression by lympho-
cytes correlate with their activation or maturation
status?
Different lymphocyte subpopulations were ana-
lyzed by flow cytometry. Mantle-zone B cells were
studied by CD39 labeling, germinal center B cells by
CD38 labeling, and dividing germinal center B cells
by CD38+CD10 labeling (Gregory et al., 1987; Liu et
al., 1992; Hardie et al., 1993; Lagresle et al., 1993;
MacLennan, 1994; Kremmidiotis and Zola, 1995;
Lagresle et al, 1995; Dono et al., 1996). A peculiar
population of T cells has been found inside the
germinal centers; these cells are CD4+, most of them
are CD57 (Velardi et al., 1986; Bouzahzah et al.,
1996a). On the basis of CD57 expression, we purified
them by MACS and analyzed their hGH-N-R
expression. Activated cells were separated from
quiescent ones by Percoll-gradient centrifugation.
Expression of hGH-N-R was revealed by two
different means: with mAb263 (mouse anti-hGH-N-
R) and with FITC-labeled hGH-N. Since both meth-
ods gave similar results (to be published), we present
here the results obtained with hGH-N/FITC.
By double labeling (anti-CD/PE and hGH-N/
FITC), we identified cell types and checked their
hGH-N-R expression.
MATERIAL AND METHODS
Antibodies
Phycoerythrin (PE)-conjugated anti-CD3, anti-CD 10,
anti-CD19, and unconjugated anti-CD19 and anti-
CD8 monoclonal antibodies were provided by DAKO
(Denmark). Simultest anti-CD3/FITC/CD19/PE, anti-
CD38/PE, and biotinylated anti-CD57 mAbs were
purchased from Becton-Dickinson (Rutherford, NJ).
Rabbit anti-human Ig coupled to polyacrylamide
beads was produced by Biorad Laboratories (Rich-
mond, VA) and used at 1/600 final dilution. Anti-
CD39/PE mAb was provided by Pharmingen (USA)
and streptavidinE by Boehringer Mannheim (Ger-
many). OKT3 and OKTll mAbs were kindly pro-
vided by Thierry de France (Lyon, France) and
mAb263 was a gracious gift from Ross Barnard
(Queensland, Australia).
Isolation of T Cells
Tonsils from 1 to 8-year-old children were surgically
removed and carried to the laboratory at 4C in a
physiological solution containing 0.4% BSA (Sigma,
USA). Lymphocyte populations were prepared by
gently teasing the tonsils. Free cells were harvested
and T cells were separated by rosetting using sheep
red blood cells (SRBC), treated with 2-aminoethylth-
iouronium, on a Ficoll Paque gradient (Pharmacia,
Sweden). CD3 cells were selected by eliminating
CD19 cells from the rosetted population (Bouzahzah
et al., 1996b). For this, the cells were incubated with
mouse anti-CD19 antibodies before rinsing and
adding Dynabeads-coupled anti-mouse IgG (Dynal,
Norway). Labeled B cells were eliminated in a
magnetic field. The purity of the T cells usually
exceeded 95%, as determined by cytofluorometry
(FACScan, Becton-Dickinson, USA).
CD4 lymphocytes were purified similarly with
anti-CD19 and anti-CD8 mAbs and Dynabeads.
CD4+CD57 T cells were prepared (Bouzahzah et
al., 1995) by means of a magnetic cell sorter (MACS,
Becton-Dickinson, USA): Briefly, CD4 cells were
incubated for 30 min at 4C with anti-CD57 mAb,
then rinsed and placed in contact with PE-conjugated
avidin and biotinylated magnetic beads (Sanvertec,
The Netherlands). The cells were transferred to a
separation column in the magnetic field of a MACS
apparatus. CD4+CD57 cells passed through the
column, CD57 cells were retained by the magneticHGH-N-R IN HUMAN TONSILAR LYMPHOCYTES 297
field. The resulting CD57 and CD57- cells prepara-
tions were respectively 90% and 95% pure.
Bovine serum albumin (1 mg/ml BSA, Sigma) was
conjugated to FITC by the same protocol and used as
a negative control.
Isolation of B Cells
Of the nonrosetted cells, around 90% were B cells
(CD19+). The concentration of B cells was improved
to 95% and 98% of total population by eliminating the
contaminating T cells with OKT3 and OKTll and
then Dynabeads (Bouzahzah et al., 1995).
Percoll Gradients
Tonsillar cells were separated (Cleary et al., 1995) by
density centrifugation into high- and low-density cells
on a discontinuous 30/50/100 % Percoll (Pharmacia,
Sweden) gradient (1100 g; 12 min). High-density
cells were collected at the 50/100 % interface, and
low-density cells at the 30/50 % interface. To
preserve isotonicity (1 PBS), the Percoll was
diluted in PBS. Thus, 100% Percoll is defined as
commercially available pure Percoll diluted in 0.1
volume of 10 PBS, 50% Percoll is a 1/1 dilution of
Percoll in 1 PBS, and 30% Percoll is obtained by
mixing 0.6 volume of Percoll with 1.4 volume of 1
PBS.
Preparation of hGH-N/FITC
Recombinant human GH-N (Kabi, Sweden) was
coupled (Badolato et al., 1994; Rapaport et al., 1995)
to FITC (Sigma). This was done as follow: hGH-N (1
mg/ml) was dissolved in 0.1 M sodium bicarbonate
buffer, pH 9-9.4. FITC (1 mg/ml) was dissolved in
dimethylsulfoxyde (DMSO, Sigma). A 250-/xl FITC
solution was added to the dissolved hGH-N in 30-/xl
aliquots dispensed at 15-sec intervals under constant
stirring. The mixture was then incubated overnight in
darkness at 4C. Free FITC was removed by three
rounds of dialysis against 1000 volume of sodium
bicarbonate buffer solution. This was performed at
4C in the dark.
The protein concentration and the fluorescein/
protein ratio (F/P) were determined by optical densi-
tometry at 280 nm (protein) and 492 nm (FITC).
Fluorescein Labeling
Binding ofhGH-N/FITC was evaluated by incubating
106 lymphocytes with 5 /xg hGH-N/FITC or BSA/
FITC in PBS, pH 7.4, for 1 hr at 4C in the dark.
BSA/FITC was used as a negative control. After 30
min, PE-conjugated mAbs (anti-CD3, -CD10, -CD19,
-CD38, or-CD39) were added at the adequate
dilution. The cells were then washed twice in 1 ml
cold PBS, resuspended in 750 /xl cold PBS, and
analyzed with the FACScan.
RESULTS
Saturation Curve
To test the capacity of hGH-N/FITC to bind hGH-N
receptors of living cells, we prepared tonsillar lym-
phoid cells, labeled them with anti-CD19/PE to stain
B cells, and incubated them with increasing amounts
of hGH-N/FITC before measuring the percentage of
FITC-positive cells with the FACS. The results
indicate that saturation level begins at approximately
5/xg/ml (Figure 1). BSA/FITC was used as a negative
control (Rapaport et al., 1995). The binding speci-
ficity of hGH-N/FITC has previously been proven by
blocking with unlabeled hGH (Igout et al., 1995). The
subsequent experiments were performed with 5 /xg
hGH-N/FITC/ml, which enabled us to label a high
percentage of hGHN-R while limiting non-specific
binding.
Total B- and T-Cell Populations
Crude and cultured lymph-cell populations were
double-labelled with hGH/N-FITC and anti-CD3/pE
(for T lymphocytes) or anti-CD19/PE (for B lympho-
cytes) mAbs. The results (Table I and Figures 2 and 3)
obtained from six tonsils show that practically no T
cell express hGHN-R wherease 60-95% of B cells
express it. These percentages are underestimated,298 OLIVIER THELLIN et al.
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FIGURE Saturation curve; ordinate: percentages of cells having bound hGH-N/FITC; abscissa: concentration of hGH-N/FITC.
since we used a nonsaturating concentration of hGH-
N/FITC to stain the cells. Furthermore, experiments
showed a strong rise in hGHN-R expression by T
cells when these cells were activated by culturing for
24 or 48 hours in DMEM/F-12 with phycohemag-
glutinin L (PHA-L; 2 /xg/ml); hGHN-R expression
also increased, but to a lesser extent, in lipopoly-
saccharide-activated B cells (10 /xg/ml lipopoly-
saccharide; same culture conditions) (data not
shown). In the tonsil, most T cells thus appear not to
express hGHN-R, whereas nearly all B cells exhibit a
basal expression level. To verify this pattern of
hGHN-R expression, we prepared and studied iso-
lated tonsillar B- and T-cell subpopulations.
TABLE Expression of hGHN-R by of Tonsillar B and T
lymphocytes (%)
Tonsil no. CD3 cells CD19 cells
<5 67
2 (rosetted cells) <5 63
3 <5% 82
4 ND 77
5 ND 76
6 <5 95
T-Cell Subpopulations
We double-labeled subpopulations of T cells (CD4/,
CD8+, or CD57+) in mixed B-, T-cell populations and
purified CD3 or CD4+CD57 cells with hGH-N/
FITC. The results (Table II and Figure 2) show that in
all tonsillar T-cell subpopulations, even for the CD57
subpopulation, less than 5% of the cell express
hGHN-R. No difference was seen between the CD4
and CD8 populations. Incubation of these cells with
PHA-L enhanced their hGH-N-R expression (data to
be published).
B-Cell Subpopulations
Crude B-, T-cell populations or purified CD19 B
cells were double-labeled with hGH-N/FITC and with
anti-CD10, anti-CD19, anti-CD38, or anti-CD39/PE
mAbs (Figure 4). The Mann-Whitney test was not
applicable to either preparations because the results
varied considerably from tonsil to tonsil (six tonsils, ce
5%) (Table III and Figure 3). To analyze differences
between cell subpopulations, we thus examined each
tonsil separately. In all six tonsils, CD38 and CD39
cells were found systematically to express more
hGHN-R per cell than CD38/CD10 cells. Since this
is probably due to the proliferation status ofHGH-N-R IN HUMAN TONSILAR LYMPHOCYTES 299
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FIGURE 2 Percentages of T-cell subpopulations expressing hGH-N-R.300 OLIVIER THELLIN et al.
CD38/CD10 cells, we investigated hGH-N-R
expression among high-density (nonactivated) and
low-density (activated) tonsillar B and T lymphoid
cells, separated on Percoll gradients.
T-Cell Gradients
between tonsils, constantly show that more low-
density T cells express hGHN-R than high-density T
cells. The percentage of hGH-N-R positive cells is
lower, nevertheless, among activated (low-density) T
cells than in the corresponding low-density B-cell
population.
Unseparated lymph cells were centrifuged on Percoll
gradients, yielding high-density (small, nonactivated)
and low-density (large, activated) cells. Both popula-
tions were investigated by double-labeling with hGH-
N/FITC and anti-CD3/PE, anti-CD4/PE, or anti-CD8/
PE mAbs. The results (Table IV), highly variable
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Unseparated lymph cells were centrifuged on Percoll
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and low-density (large, activated) cells. Both popula-
tions were investigated by double-labeling with hGH-
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TABLE II Expression of hGH-N-R by Tonsillar T-Cell Subpopulations (%)
Tonsil no. CD4 cells CD8 cells CD4/CD57 cells CD4/CD57 cells
(rosetted cells) ND ND <5 <5
2 ND ND <5 <5
3 <5 <5 ND ND
4 <5 <5 ND ND
5 ND ND <5 <5
N/FITC and anti-CD10/PE, anti-CD19/PE, anti-
CD38/PE, or anti-CD39/PE mAbs. The results (Table
V and Figure 5) show that low-density B cells express
slightly more hGHN-R than high-density B cells and
also more than the total B-cell population prior to
separation. The hGH-N-R density varies on low-
density B cells according to cell type: CD10 cells
express less hGHN-R than other cell types. Here
again, high variability between tonsils is apparent, but
the results for each tonsil show a higher percentage of
labeled cells in the low-density population. In both the
high- and low-density populations, fewer
CD38/CD10 cells than CD38/CD10- or CD39 cell
express the receptor.
DISCUSSION
Germinal centers develop in the secondary follicles of
lymphoid organs by B-cell proliferation during a T-
cell-dependent antibody response (MacLennan et al.,
1992; MacLennan, 1994). Each germinal center is
divided into a dark and a light zone. Centroblasts
proliferate in the dark zone, and, migrating to the light
zone, mature in contact with antigen-presenting
follicular dendritic cells (FDC). During their matura-
tion, CD38/CD10 B cells first lose CD 10, then CD38
at the end of maturation (Kremmidiotis and Zola,
1995), and finally CD39 after maturation has finished
(Lagresle et al., 1993).
T-dependent
zone
Mantle zone
CD39+
Germinal center
light zone
CD38+CD10-
Germinal center
dark zone
CD38+CD10+
FIGURE 4 Schematic representation of a secondary lymph follicle in relation to a B-cell phenotype.302 OLIVIER THELLIN et al.
TABLE III Expression of hGH-N-R by tonsillar B cell subpopulations (%)
Tonsil no. CD38 cells CD38+CD10 cells CD39 cells
64 59 72
2 (rosetted cells) 72 63 65
3 87 62 84
4 86 68 75
5 ND 70 ND
6 ND 87 89
TABLE IV Expression of hGH-N-R by Quiescent (High-Density) or Activated (Low-Density) T Cells
Tonsil no. High-density T cells Low-density T cells
CD3 CD4 CD8 CD3 CD4 CD8
<5 ND ND 12 ND ND
2 <5 <5 <5 69 75 75
3 <5 <5 <5 25 22 26
TABLE V Expression of hGH-N-R by Quiescent (High-Density) or Activated (Low-Density) B Cells (%)
Tonsil no. High-density B cells Low-density B cells
CD19 CD10 CD38 CD39 CD19 CD10 CD38 CD39
70 55 60 70 83 81 83 82
2 73 53 60 57 82 76 80 80
3 92 90 85 85 95 92 97 95
4 91 89 93 92 95 91 97 96
Kiess and Butenandt (1985) have detected hGHN-
R on mononuclear cells from peripheral venous
blood. Here we have investigated the capacity of
subpopulations of tonsillar B and T lymphocytes to
express hGHN-R. Using fluorescein-labeled human
growth hormone, cytometry, and cell-selection proce-
dures, we have obtained new data on hGHN-R.
Unlike tonsillar T cells, tonsillar B cells constitutively
express these receptors. T cells do so transiently when
activated. Interestingly, the peculiar CD4/CD57
germinal center T cells do not express hGH-N-R. This
confirms data from other authors, indicating that these
cells are only in a preactivated state (Bouzahzah et al.,
1995).
Among the follicular B cells, the dark-zone
CD38+CD10 B cells possess few hGH-N-R. Perhaps
proliferation causes B cells to reduce the density of
hGH-N-R on their surface: During proliferation,
activated cells express less hGH-N-R.
These differences between B and T cells and
between resting and proliferating cells were observed
on both mixed (crude) and purified lymphoid-cell
populations and after centrifugation in Percoll. The
results are confirmed by in vitro studies on mitogen-
activated lymphoid cells (in preparation). Contamina-
tion by other cells bearing the CD of interest does not
appear significant, since most of our data were
obtained on highly purified B- or T-lymphocyte
populations.
Since lymphocyte activation requires antigen rec-
ognition and costimulatory signals given by accessory
or lymphoid cells, we can now hypothesize that
activated cells bear higher numbers of certain recep-
tors rendering them particularly receptive to mes-
sages, such as growth hormone, from the neuroendo-
crine system. Quiescent B cells appear more sensitive
to growth hormone signaling than T cells, but
activation opens the latter to the influence of growthHGH-N-R IN HUMAN TONSILAR LYMPHOCYTES 303
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hormone. The sensitivity of the immune system to
signals of the neuroendocrine system thus depends on
its stimulation level.
These observations reinforce the view that hGH-N
is part of the immune system regulation machinery.
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